Xiudong Lei

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. doi request reprint Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
    Xiudong Lei
    Department of Biostatistics, Unit 1411, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Lifetime Data Anal 17:156-74. 2011
  2. pmc Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
    Amal Melhem-Bertrandt
    The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    J Clin Oncol 29:2645-52. 2011
  3. pmc Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Clin Cancer Res 17:6052-60. 2011
  4. doi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3224-31. 2011
  5. doi request reprint High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
    Donald A Berry
    Division of Quantitative Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3214-23. 2011
  6. pmc Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model
    Kiran Naqvi
    The University of Texas MD Anderson Cancer, Houston, TX 77030, USA
    J Clin Oncol 29:2240-6. 2011

Collaborators

  • Guosheng Yin
  • Ying Yuan
  • Donald A Berry
  • Amal Melhem-Bertrandt
  • Taner Demirer
  • John P Crown
  • Naoto T Ueno
  • Marcella M Johnson
  • Marco Bregni
  • Aung Naing
  • Jean Caputo
  • Kiran Naqvi
  • Gabriel N Hortobagyi
  • Razelle Kurzrock
  • Hagop M Kantarjian
  • Richard T Lee
  • Naifa Busaidy
  • Guillermo Garcia-Manero
  • Elisabeth G E de Vries
  • Ulrike A Nitz
  • Giovanni Rosti
  • Jean Pierre Lotz
  • Robert C Leonard
  • Lance K Heilbrun
  • Funda Meric-Bernstam
  • Martin S Tallman
  • William E Barlow
  • Ana Maria Gonzalez-Angulo
  • Eric Rohren
  • Sachin Gupta
  • Sjoerd Rodenhuis
  • Dori A Smith
  • Suzanne D Conzen
  • Angelika Burger
  • Chandtip Chandhasin
  • Lawrence A Doyle
  • David Hong
  • Henri Roche
  • Anil K Sood
  • Axel R Zander
  • Patricia LoRusso
  • Chaan Ng
  • Russell L Basser
  • Sagar Sardesai
  • Mariana Chavez-MacGregor
  • Helen X Chen
  • Pierre Biron
  • William P Peters
  • Paolo Pedrazzoli
  • Alessandro M Gianni
  • Carlos E Vigil
  • Michael Crump
  • R Charles Coombes
  • Erika N Brown
  • Jeong Oh
  • Jianqin Shan
  • Edward A Stadtmauer
  • Maria E Suarez-Almazor
  • Jonas Bergh
  • Peter Schmid
  • Linda J Yancey
  • Yutaka Tokuda
  • Sherry Pierce

Detail Information

Publications6

  1. doi request reprint Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
    Xiudong Lei
    Department of Biostatistics, Unit 1411, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Lifetime Data Anal 17:156-74. 2011
    ..D. Anderson Cancer Center, we conduct extensive simulation studies under various scenarios to investigate the performance of the proposed method, and compare it with available Bayesian adaptive randomization procedures...
  2. pmc Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer
    Amal Melhem-Bertrandt
    The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA
    J Clin Oncol 29:2645-52. 2011
    ..To examine the association between beta-blocker (BB) intake, pathologic complete response (pCR) rates, and survival outcomes in patients with breast cancer treated with neoadjuvant chemotherapy...
  3. pmc Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer
    Aung Naing
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, MD Anderson Cancer Center, University of Texas, Houston, Texas, USA
    Clin Cancer Res 17:6052-60. 2011
    ..The objectives of this phase I study were to evaluate the tolerability and activity of temsirolimus and cixutumumab...
  4. doi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3224-31. 2011
    ....
  5. doi request reprint High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
    Donald A Berry
    Division of Quantitative Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3214-23. 2011
    ..Individual trials have had limited power to show overall benefit or benefits within subsets...
  6. pmc Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model
    Kiran Naqvi
    The University of Texas MD Anderson Cancer, Houston, TX 77030, USA
    J Clin Oncol 29:2240-6. 2011
    ..Patients with cancer often experience comorbidities that may affect their prognosis and outcome. The objective of this study was to determine the effect of comorbidities on the survival of patients with myelodysplastic syndrome (MDS)...